Science

our pipeline

We are advancing a pipeline of GMAR T^TM candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Our GMAR T portfolio includes rights to 15 preclinical GMAR T cell therapy targets licensed from SmithKline Beecham and U.S. rights to clinical candidates GMART-501 and SKBT42 licensed from Servier, currently in Phase 1 development for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) and relapsed/refractory acute lymphoblastic leukemia (ALL), respectively.

¹ Phase 3 may not be required if Phase 2 is registrational
² Servier will hold ex-US commercial rights. Servier is the sponsor of the SKBT42 trials
³ Gridiron is the sponsor of the GMART-501 trial and expected sponsor of the GMART-501A trial
⁴ GMART-647 intended to enable expansion and persistence of Reitec GMAR T product candidates
⁵ Gridiron sponsored trial in combination with SpringWorks Therapeutics; Initiation expected 2H 2020